Pre-made Ontuxizumab benchmark antibody ( Whole mAb, anti-CD248 therapeutic antibody, Anti-CD164L1/TEM1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-405

Pre-Made Ontuxizumab biosimilar, Whole mAb, Anti-CD248 Antibody: Anti-CD164L1/TEM1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ontuxizumab is a humanized rabbit monoclonal antibody designed for the treatment of cancer. It binds to endosialin (TEM1 or CD248).

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-405-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Ontuxizumab biosimilar, Whole mAb, Anti-CD248 Antibody: Anti-CD164L1/TEM1 therapeutic antibody
INN Name Ontuxizumab
TargetCD248
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesLudwig Institute for Cancer Research;Morphotek;National Cancer Institute (USA)
Conditions Approvedna
Conditions ActiveColorectal cancer;Malignant melanoma;Soft tissue sarcoma
Conditions DiscontinuedLymphoma;Solid tumours
Development Techna